PCI Makes Significant Irish Investment Ahead of Brexit

Article

PCI has divulged that it is making significant investment at its site near Dublin, Ireland to strengthen its position globally and to ensure pharmaceutical supply is uninterrupted for its customers after Brexit.

PCI has divulged that it is making significant investment at its site near Dublin, Ireland to strengthen its position globally and to ensure pharmaceutical supply is uninterrupted for its customers after Brexit, which is set to happen on Oct. 31, 2019.

The investment will be used to build a dedicated clinical facility that will, once completed, provide more than 75,000 sq. ft. of space to the business, which will be used as a center for primary and secondary packaging, storage, logistics, and distribution. Forming a part of the company’s overall global expansion plans, the new Irish facility will increase capabilities and capacity for the clinical services business.

“Our growth strategy is focused on the continued expansion of our global network to support growing demand from our customers and providing a solution for Brexit through ongoing investment in capacity, capability expansion and talent,” said PCI chief executive officer Salim Haffar in an Aug. 27, 2019 press release. “We are very pleased with our team’s progress in expanding our global footprint as we partner with our customers in the shared goal of improving patients’ lives.”

Source: PCI

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content